Drugs Made In (DMAA) Fundamental Analysis: Revenue, Earnings & Valuation

4.04 / 10

Netural

The company exhibits mixed fundamental metrics (4.0/10). Strengths observed in Operating cycle and Inventory turnover ratio, while concerns exist in Diluted earnings per share (YoY growth rate %). Lead to constrained appraisal.

Analysis Checks(9/10)

Operating cycle

Value231.47

Score2/3

Weight8.26%

1M Return1.16%

Inventory turnover ratio

Value47.74

Score2/3

Weight9.52%

1M Return1.35%

Gross profit margin (%)

Value36.93

Score2/3

Weight9.98%

1M Return1.38%

Rate of return on total assets (%)

Value-0.61

Score2/3

Weight10.06%

1M Return1.45%

Fixed assets turnover ratio

Value7871.26

Score3/3

Weight21.59%

1M Return2.94%

Annualized return on total assets (%)

Value-0.81

Score2/3

Weight10.06%

1M Return1.45%

Diluted earnings per share (YoY growth rate %)

Value898.28

Score1/3

Weight6.56%

1M Return0.92%

Asset-MV

Value-0.45

Score2/3

Weight4.76%

1M Return0.67%

Current assets / Total assets (%)

Value0.01

Score2/3

Weight10.69%

1M Return1.46%

Current ratio

Value0.06

Score2/3

Weight8.53%

1M Return1.20%

Is DMAA fundamentally strong?

DMAA scores 4.04/10 on fundamentals and holds a Fair valuation at present. Backed by its 4.98% ROE, 0.00% net margin, 62.40 P/E ratio, 1.53 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.